Jack Meng-Fen Su, MD
His clinical interest is in neuro-oncology.
Dr. Jack Su's research interest is in translational oncology and developing novel agents for treating pediatric CNS tumors. Dr. Su is currently conducting a Children's Oncology Group phase I study of valproic acid in children with recurrent solid tumors, including brain tumors. He is also developing clinical trials of additional histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), and a poly(ADP-ribose) polymerase (PARP) inhibitor for pediatric CNS tumors. In collaboration with Drs. Xiao-Nan Li, Susan Blaney, and Ching Lau, Dr. Su is conducting pre-clinical studies of HDAC inhibitors, PARP inhibitors, and DNA methylation inhibitors for future clinical trials in pediatric CNS tumors.His research interests are in translational oncology and developing novel agents for treating pediatric CNS tumors.
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.